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HumanA multi-compartment physiologically based pharmacokinetic (PBPK) model was developed to describe
the behavior of Cr(III) and Cr(VI) in humans. Compartments were included for gastrointestinal lumen,
oral mucosa, stomach, small intestinal tissue, blood, liver, kidney, bone, and a combined compartment
for remaining tissues. As chronic exposure to high concentrations of Cr(VI) in drinking water cause small
intestinal cancer in mice, the toxicokinetics of Cr(VI) in the upper gastrointestinal tract of rodents and
humans are important for assessing internal tissue dose in risk assessment. Fasted human stomach ﬂuid
was collected and ex vivo Cr(VI) reduction studies were conducted and used to characterize reduction of
Cr(VI) in human stomach ﬂuid as a mixed second-order, pH-dependent process. For model development,
toxicokinetic data for total chromium in human tissues and excreta were identiﬁed from the published
literature. Overall, the PBPK model provides a good description of chromium toxicokinetics and is consis-
tent with the available total chromium data from Cr(III) and Cr(VI) exposures in typical humans (i.e.,
model predictions are within a factor of three for approximately 86% of available data). By accounting
for key species differences, sources of saturable toxicokinetics, and sources of uncertainty and variation,
the rodent and human PBPK models can provide a robust characterization of toxicokinetics in the target
tissue of the small intestine allowing for improved health risk assessment of human populations exposed
to environmentally-relevant concentrations.
 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY license.1. Introduction centrations of Cr(VI) in environmental media is generally attrib-Human exposures to low concentrations of hexavalent chro-
mium, Cr(VI), are widespread throughout the United States [1,2]
and around the world [3,4]. Although the occurrence of high con-uted to industrial releases, low concentrations of Cr(VI) in
drinking water are prevalent from natural sources associated with
Cr-enriched geology [1,3,5]. In addition to groundwater, low con-
centrations of Cr(VI) have been reported in urban household dust
[6] and in some foods [7]. Because of this widespread exposure
to Cr(VI), the potential for adverse health effects is of signiﬁcant
public health interest.
Chronic exposures to high concentrations of Cr(VI) in drinking
water (orders ofmagnitude above those encountered in theenviron-
ment) has been shown to increase the incidence of small intestinal
tumors in mice, and oral cavity tumors in rats [8,9]. Although occu-
pational exposure to Cr(VI) has been shown to cause lung cancer
among workers in certain industries, and is known to induce respi-
ratory tumors in animals following inhalation and intrabronchial
administration [10], oral exposures were not previously thought to
pose a cancer risk because most Cr(VI) is reduced to the trivalent
14 C.R. Kirman et al. / Chemico-Biological Interactions 204 (2013) 13–27form [Cr(III)] in the acidic environment of the stomach lumen at
environmentally relevant concentrations [11,12]. In addition,
Cr(VI)-exposed workers have not been shown to have an increased
risk of gastrointestinal (GI) tract cancers, including oral cavity and
small intestinal cancers [13]. Thus, theobservationofGI tract tumors
in rodents raises important questions regarding interspecies as well
as high-to-lowdose extrapolation used to estimate cancer risk asso-
ciated with low-dose ingestion of Cr(VI) in humans.
Due to analytical limitations [i.e., difﬁculty in speciating Cr(III)
and Cr(VI)], only total chromium has been measured in tissues
and excreta of animals exposed to Cr(VI). Because measurements
for total tissue chromium may not be the best internal dose mea-
sure for assessing cancer risk attributable to Cr(VI) exposures, a
physiologically based pharmacokinetic (PBPK) model is needed to
characterize reduction of Cr(VI)–Cr(III) prior to absorption and esti-
mate internal doses for speciated chromium. Previous PBPK mod-
els for Cr(VI) and Cr(III) have been developed for rats and
humans [14,15], but they do not include compartments and
parameterization for the GI tract. More recently, a PBPK model
was developed for oral exposures to Cr(III) and Cr(VI) in rats and
mice [16], which includes compartments for target tissues of inter-
est (small intestines and oral cavity) and incorporates ex vivo data
for the reduction of Cr(VI) in rat and mouse gastric contents [17].
The work presented here is part of a multifaceted research ef-
fort to provide the data and tools needed to support human health
risk assessment for Cr(VI). The study was designed using US EPA
risk assessment guidance [18] to address data gaps in the hypoth-
esized mode of action (MOA) for Cr(VI) in mouse small intestines
[19,75]. To date, these efforts have resulted in publications on
the reduction of Cr(VI) in rodent gastric contents [17], analysis of
toxicogenomic responses in rodent small intestines [20,21,76],
and evaluation of biochemistry and histopathology in mouse and
rat oral mucosa and small intestine [22,23]. In addition, a PBPK
model has been developed for Cr in rodents [16]. The current study
includes ex vivo data on the rate and capacity of Cr(VI) reduction in
fasted human gastric ﬂuid. The goal of the humanmodel developed
here was to determine the rate and extent of absorption for Cr(III)
and Cr(VI) from available human data sets, so that estimates of
internal dose to the small intestine can be made. PBPK model-de-
rived target tissue doses for the small intestines will be used to
support quantitative risk assessment for oral exposures to Cr(VI),
and to provide a more scientiﬁcally supportable basis than default
methods for interspecies and high-to-low-dose extrapolations.2. Materials and methods
2.1. Ex vivo studies of Cr(VI) reduction kinetics in human gastric ﬂuid
Wepreviously reported the kinetics of Cr(VI) reduction in rodent
stomach contents [17]. It was determined that the reduction of
Cr(VI) occurred by a mixed second-order model in which the rate
of Cr(VI) reductionwas dependent upon the concentrations of Cr(VI)
and reducing agents present in the stomach contents. The experi-
ments in rodent stomach contents were conducted at a range of
Cr(VI) spiking concentrations and dilutions so as to assess reduction
under conditions consistentwith that of recent rodent 90-dayand2-
year bioassays [9,22,23]. Second-order rate constants (k) inmice and
rats at pH = 4.5 were 0.2 and 0.3 L mg1 h1, respectively, and the
reducing capacity of gastric contents was approximately 16 mg
Cr(VI) reducingequivalentsper Lof stomachcontents inbothspecies
[17].
De Flora et al. [24] determined the extent of Cr(VI) reduction in
fasted and fed human stomach contents, but only at a single time
point (60 min). Therefore, their results are best used to character-
ize reduction capacity, rather than rate. De Flora et al. [24] foundthat the capacity of human stomach ﬂuid to reduce Cr(VI) was in-
versely related to pH (e.g., less reduction capacity at higher pH),
but was also highest following the start of a meal (post-prandial)
as compared to in a fasted state despite a higher post-prandial
pH. A strong pH dependence has been reported for the rate of
reduction of Cr(VI) by glutathione [25], one of several potential
reducing agents in the intestinal lumen. Thus, pH of the gastric
ﬂuid, and the presence of food (as source of reducing agents such
as ascorbic acid) were considered to be important factors affecting
Cr(VI) reduction in human stomach ﬂuid.
Ex vivo studies using fasted human gastric ﬂuids were con-
ducted to assess the rate and capacity for Cr(VI) reduction. Patients
were fasted for a minimum of 7 h. The samples were collected from
anonymous patients, and the study was declared to be work not
involving human subjects by the Duke Institutional Review Board.
Samples of gastric ﬂuid were collected from 10 fasting preopera-
tive cardiac patients at Duke University Hospital who were not
on proton pump inhibitors (PPIs). Between one and 10 mL of gas-
tric ﬂuid were collected from each of the 10 patients, yielding a to-
tal gastric ﬂuid volume of approximately 34 mL. In addition, to
understand the effect of PPI use on gastric pH and Cr(VI) reduction,
additional gastric ﬂuid samples (2–3 mL) were collected from each
of 5 patients on PPIs at Duke University Hospital, yielding a total
gastric ﬂuid volume of approximately 11 mL.
Samples of all 10 patients not on PPIs were pooled based on pH
such that three pools were generated: (1) a pool with a pH of 1
(n = 3); (2) a pool with a pH of 2 (n = 2); and (3) a pool with a
pH of 4 (n = 5). The samples from the 5 patients who were on PPIs
were used to create a separate pool with a pH of 7. The ex vivo
approach to quantifying reduction kinetics of Cr(VI) in stomach ﬂu-
ids using speciated isotope dilution mass spectrometry (SIDMS)
have been described previously [17]. The limit of detection in
10:1 diluted stomach ﬂuid samples varied from sample to sample
but was generally less than 5 ppb.
2.2. Human PBPK model development
Information from the published literature regarding the toxic-
okinetics of chromium in humans was reviewed to identify key
data sets that could be used to support the PBPK model develop-
ment. These data include controlled exposures of human volun-
teers to Cr(III) and/or Cr(VI), and case reports of accidental or
intentional poisonings with Cr(VI).
Although a PBPK model has been developed previously for chro-
mium in humans [14], inspection of the model structure, parame-
terization, and predicted behaviors revealed that it would not be
easily modiﬁed to reﬂect the key processes identiﬁed for assessing
Cr toxicokinetics in GI compartments. For this reason a new con-
ceptual and a new PBPK model were developed for human oral
exposures to chromium. Code for the human PBPK model was
adapted from the rodent PBPK model [16] to describe the key tox-
icokinetic processes identiﬁed in the conceptual model. All PBPK
modeling was performed in Advanced Continuous Simulation Lan-
guage eXtreme (acslX) along with its interface for Excel (Aegis TG,
version 3.0). Model parameter values were set based on: (1) data
from the published literature; (2) by adjusting parameter values
to obtain ﬁts to the key data sets; and (3) professional judgment.
The general approach to modeling the chromium data sets in-
volved ﬁrst deﬁning model parameter values for Cr(III), then hold-
ing the parameters for Cr(III) toxicokinetics and for Cr(VI)
reduction ﬁxed, and ﬁnally adjusting the Cr(VI) model parameters
to obtain ﬁts to the key data sets identiﬁed for Cr(VI). Code was in-
cluded in the model to track chromium mass-balance (see Appen-
dix A), and all model simulations were checked to ensure mass-
balance was maintained. The data sets of Finley et al. [26] were
not used to estimate model parameters, but were instead held back
C.R. Kirman et al. / Chemico-Biological Interactions 204 (2013) 13–27 15to be used for model validation purposes. To help identify impor-
tant model parameters, a sensitivity analysis was conducted for
the humanmodel by increasing individual model parameter values
one at a time by 5% over their default values for a deﬁned exposure
simulation (exposure to 0.05 mg/kg spread over 5 equal bolus
exposure events per day) and noting the percent change in value
predicted by the model for several internal dose measures.
3. Theory
3.1. Key data sets
Key data sets for understanding the toxicokinetics of Cr(III) and
Cr(VI) in humans are listed in Table 1. Overall, the data collected
for Cr(III) support a conclusion that the oral absorption following
short-term exposures is low (0.1–2%), and that absorbed Cr is pri-
marily excreted in the urine. Similarly, the data collected for Cr(VI)
support a conclusion that the oral absorption of chromium [as a
mixture of Cr(III) and Cr(VI) from the GI lumen] is higher than that
of Cr(III), but still low, and that Cr that is absorbed is primarily ex-
creted in the urine.
In reviewing toxicokinetic data for rodents [16], two important
patterns were identiﬁed:
(1) The ratio of chromium concentrations in erythro-
cytes:plasma serves as a potential biomarker for systemic
Cr(VI) absorption. This ratio is generally one or less for Cr(III)
exposures and low-dose exposures to Cr(VI), but increases
above one for sufﬁciently high exposures to Cr(VI). At doses
of Cr(VI) that exceed the GI tract capacity for reduction,
Cr(VI) reaching portal plasma can enter portal erythrocytes.
Following intracellular reduction to Cr(III), which is much
less permeable to cell membranes, chromium becomes
effectively ‘‘trapped’’ within erythrocytes.
(2) There are clear species differences in the liver:kidney ratio of
tissue chromium concentrations (the ratio in mice generally
greater than one, but in rats is less than one).
These patterns appear to be relevant to humans as well. For
example, the erythrocyte:plasma ratio in humans exposed to triva-
lent chromium for 12 weeks remain below one (approximately
0.3–0.6 [32]), but ratios well above one can be calculated from data
for humans exposed to high doses (e.g., acute poisoning) of Cr(VI)
[39,40,42]. With respect to liver:kidney concentration ratios, au-Table 1
Summary of key pharmacokinetic data sets for chromium in humans.
Valence Form Reference n Exposure
Cr(III) Dichromate (reduced in OJ) Kerger et al. [31] 4 1 (5 mg
Chloride Kerger et al. [31] 5 1 (5 mg
Chloride Anderson et al. [27–29] 17–76 3 months
Chloride Mohamedshah et al. [30] 6 3 d (0.4 m
Picolinate Lukaski et al. [33] 83 12 weeks
Picolinate Volpe et al. [32] 44 12 weeks
Chloride Rubin et al. [34] 10 1 (0.3 m
Picolinate Gargas et al. [35] 8 3 (0.4 m
Cr(VI) Chromate Finley et al. [26] 5 3  3d (0
Dichromate Paustenbach et al. [36] 1 17 d (4 m
Dichromate Kerger et al. [31] 5 1 (5 mg
Dichromate Goullé et al. [42] 1 1 (800
NU = not used due to concerns that erythrocytes were not sufﬁciently rinsed to removetopsy samples for background levels of chromium in human popu-
lations [43,44] and from case reports of high-dose Cr(VI)
poisonings [37,38,40] report data that yield liver:kidney ratios
greater than one (approximately 1.4–4.3). These data suggest that,
across a broad range of exposures, the systemic distribution of
chromium in humans appears more similar to that observed in
mice than in rats. A mechanistic basis for the similarity between
mice and humans (and difference of both species from rats) with
respect to liver:kidney ratios is not known, but may suggest simi-
larities in the clearance of protein-bound forms of chromium from
these tissues in both species.
3.2. Conceptual model
A conceptual model was developed to describe the toxicokinet-
ics of chromium in rats and mice (Fig. 1 [16]). The conceptual mod-
el describes the key processes affecting Cr(VI) starting from
ingestion to excretion. Because the toxicokinetic processes are ex-
pected to be qualitatively similar across species, the conceptual
model developed for rodents [16] is considered to be equally appli-
cable to humans, and is summarized brieﬂy below.
Cr(VI) reaching the stomach becomes mixed with saliva, gastric
ﬂuid, food, and water, and while in the lumen of the stomach and
small intestines, is subject to three competing processes: (1) tran-
sit through the GI lumen sections; (2) reduction to Cr(III); and (3)
uptake/absorption into GI tissue. The reduction of Cr(VI) has been
described as a pH-dependent process [24,25]. With respect to pH, a
longitudinal gradient is present within the lumen of the stomach
and small intestines with stomach << duodenum < jeju-
num < ileum. Bicarbonate is excreted into the duodenum to neu-
tralize the acidity of the chyme (semi-ﬂuid, partially digested
stomach contents) passing from the stomach to the small intestine.
Assuming there is consistency in the availability of reducing
agents, the rate of Cr(VI) reduction in the small intestines lumen
is expected to decrease as chyme moves from the duodenum to
the ileum consistent with the increasing pH of the GI lumen. How-
ever the pH of the duodenum is approximately 6 and that of the
ileum is approximately 7 [45], and the difference in reduction rates
at these pH values is relatively small when compared to the large
change in pH that occurs between the lumens of the stomach, with
a pH of 1–3, and the duodenum with a pH of 6. Furthermore, the
change in pH between the stomach and the duodenum is much
greater in normal humans (from approximately 1.25–6) than it is
in mice (from approximately 4.5–4.9) [46,47].Plasma Erythrocytes Urine Note
) X NU X
) X NU X
(0.2 mg/d) X X
g/d) X X
(0.2 mg/d) X X
(0.4 mg/d) X X X
g) X
g/d) X
.1, 0.5, 1, 5, 10 mg/d) X NU X
g/d) X NU X Background levels for Cr
in plasma from Finley et al.
[26] were used to calculate
added Cr
/d) X NU X
mg) X X X Background levels from
Anderson et al. [27–29] and
Volpe et al. [32] used o
calculate added Cr
Cr from the erythrocyte cell membrane (personal communication, B. Kerger).
Fig. 1. Competing toxicokinetic processes for chromium in the gastrointestinal
tract: R1 = gastrointestinal transit; R2 = Cr6 reduction; R3 = Cr transport to epithe-
lium; R4 = Cr absorption into blood; R5 = Cr transit in portal plasma to the liver;
R6 = Cr in sloughed cells. Processes are depicted for a single section of the GI tract,
but are applicable to model compartments for the stomach and small intestines in
sequence.
16 C.R. Kirman et al. / Chemico-Biological Interactions 204 (2013) 13–27Within the GI tissue, Cr(VI) is subject to further reduction, while
both forms of chromium may be absorbed into portal plasma, or
returned to the GI lumen with sloughed cells. Chromium absorp-
tion is expected to occur primarily within the small intestine.
Based on rodent studies [16], the rate of uptake of chromium from
the GI lumen is greatest in the duodenum, and lower in jejunum
and ileum. However, information on the relative contribution of
small intestines sections on chromium absorption is not available
in humans. The majority of chromium in the GI lumen remains
unabsorbed and is excreted in feces.
Cr(VI) that reaches portal plasma is subject to several compet-
ing processes: (1) reduction to Cr(III); (2) uptake into erythrocytes
(followed by intracellular reduction, resulting in an increased
erythrocyte:plasma ratio as described in Section 3.1); and (3) tran-
sit to the liver and systemic tissues. Based upon evaluation of ro-
dent data [16] it is expected that, with the exception of very high
exposures (i.e., fatal poisonings), essentially all chromium entering
systemic plasma from the hepatic/portal system will have been re-
duced to Cr(III). The distribution of Cr(III) from plasma to tissues is
largely determined by its binding to transport proteins [48–50],
which may help to explain how plasma chromium levels remain
relatively low despite much higher concentrations in mammalian
tissues [8,51]. Transferrin, a protein that is important for delivery
of iron to tissues, possesses two binding sites, one of which has a
high afﬁnity for Cr(III) (i.e., Cr(III) will displace iron at neutral
pH) [48], and therefore is expected to play a role in the delivery
of Cr(III) from the GI tract to tissues. A low-molecular weight pro-
tein that is capable of tightly binding Cr(III) has been detected in a
number of mammalian tissues [48,52–54], and may play a role in
transport from tissues to kidney and its ultimate excretion in urine.
Biliary excretion of chromium is expected to be negligible [15].Fig. 2. Ex vivo reduction of Cr(VI) in human stomach ﬂuid collected from
preoperative cardiac patients: (A) Time-course data for Cr(VI) spike concentration
of 1 ppm, gastric ﬂuid dilution of 10:1, pH = 1.3 (n = 10); (B) Time-course data for
Cr(VI) spike concentration of 0.1 ppm, gastric ﬂuid dilution of 10:1, pH = 4; and (C)
Relationship between pH and Cr(VI) reduction rate constant. Diamonds = data
points, lines = reduction model predictions.4. Results
4.1. Ex vivo studies of Cr(VI) reduction kinetics in human gastric ﬂuid
Similar to rodent gastric contents, the kinetics of Cr(VI) reduc-
tion in fasted human stomach ﬂuid exhibited mixed second order
reaction kinetics. For the sake of simplicity, reducing agents within
gastric ﬂuid were treated as a single, lumped pool of reducing
equivalents. The reduction reaction of Cr(VI) in fasted stomach
ﬂuid samples was found to be inversely related to pH (highest ratesof Cr(VI) reduction occurring at lower pH values). Representative
curves are provided in Fig. 2a,b. The second order mixed model
was ﬁt to all reduction curves and the resulting reduction rate con-
stants were found to vary as a function of pH (Fig. 2c). Based on the
data collected, a simple, empirical relationship between the reduc-
tion rate constant and pH can be described as follows (depicted in
Fig. 2c):
Kred ¼ 44:5 expðpHÞ ð1Þ
The constant of 44.5 L/mg-h estimated for humans (at pH = 0) is
slightly higher than, but within precision limits of the pH-depen-
dent values derived previously for rats (27 L/mg-h) and mice
(18 L/mg-h) [16]. A range of estimates obtained for reducing equiv-
alents in fasted human stomach ﬂuids (4 to 10 mg/L gastric ﬂuid;
mean = 7 mg/L) is consistent with the range of reducing equiva-
lents (or reductive capacity) reported by De Flora et al. [24] in
stomach ﬂuid during the fasted state (<10 mg/L). In De Flora
et al. [24], peak reductive capacity was observed during the 1–
C.R. Kirman et al. / Chemico-Biological Interactions 204 (2013) 13–27 174 h periods after each meal and the range of reducing equivalents
was reported for the fed state to be 10–60 mg/L with a median of
approximately 30 mg/L. Fed stomach ﬂuid samples could not be
obtained for our ex vivo experiment; thus, data from De Flora
et al. [24] for the fed state were used to parameterize the human
PBPK model. Therefore, estimates of reductive capacity (or reduc-
ing equivalents – mg/L) in the fed and fasted state were approxi-
mately 30 and 7 mg/L, respectively. The second order rate
constant was assumed to be the same in the fed and fasted
condition.4.2.2. Human PBPK model development
4.2.1. Model structure
Because the conceptual model for chromium in humans is qual-
itatively the same as that for rodents, the PBPK model structure de-
ﬁned for rodents was adopted for the human model (Fig. 3), and
includes model compartments for GI tract (stomach and small
intestines) and systemic tissues (blood, liver, kidney, bone, and a
lumped ‘‘other’’ tissue compartment). However, the following
changes were made to adapt the model code for ﬁtting human data
sets: (1) code was added to allow for multiple bolus exposure
events per day (up to 6/day) to accommodate the exposure regi-
mens implemented by some human studies; (2) two model param-
eters (SFin, SFout) were added to permit scaling of systemic tissue
uptake and release rate constants from mice to help ensure consis-
tency in the liver:kidney Cr concentration ratios; (3) because the
human data were generally collected at doses much lower than
those assessed in rodents, there is no need to treat absorption as
a saturable process (i.e., separate parameters for Vmax and km),
and therefore absorption was modeled in humans as a ﬁrst order
process (i.e., a single model parameter equivalent to Vmax/km);
(4) compartments for duodenum, jejunum, and ileumwere lumped
into a single compartment for the small intestines in the humanFig. 3. PBPK model structure. RBC = red blood cells; SI = small intestines; LI = large
intestines. All compartments can contain Cr(VI), light shaded arrows and compart-
ments depict Cr(III) in the distribution pool; dark shaded arrows and compartment
depict Cr(VI) in the storage/excretion pool; intermediate shaded compartments
(plasma) contain both Cr(III) pools.model since section-speciﬁc data were not available in humans
to estimate Cr uptake; and (5) the oral cavity compartment was re-
moved from the model since there are no human data available for
the oral cavity, the rapid transit rates in the oral lumen were con-
tributing substantial stiffness (i.e., requiring much smaller time
steps and longer simulation times) to the differential equations
for the GI tract portion of the model, and since it does not appear
that internal tissue dose is useful for explaining oral cavity tumor
response across species (i.e., oral cavity tissue concentrations were
higher in mice (nonresponsive for oral tumors) than rats (respon-
sive for oral tumors) [16].
Based upon the ex vivo results described in Section 4.1, the rate
constant for Cr(VI) reduction in the GI lumen was deﬁned using Eq.
1 above, and the second order rate of reduction is then calculated
as:
RRED ¼ ½CrkredRE ð2Þ
where, RRED = Rate of Cr(VI) reduction (mg/h); [Cr] = Concentration
of Cr(VI) in GI lumen (mg/L); and RE = Amount of reducing equiva-
lents in GI lumen (mg).
Cr(VI) reducing equivalents (RE) in GI lumen were modeled as a
single lumped pool that is capacity limited, with consumption and
regeneration of REs occurring as intake occurs and gastric contents
are replenished as a mixture of food, water, gastric ﬂuid, and saliva.
The reduction of Cr(VI) in GI tissues (stomach and small intestines)
was modeled as a saturable process, assuming classic Michaelis–
Menten kinetics based on erythrocyte:plasma data that suggest
that high doses of Cr(VI) can exceed the capacity of GI tissues (as
well as lumen) for Cr(VI) reduction [16].
Absorption rates for Cr(III) and Cr(VI) from the GI lumen into
tissues were modeled as ﬁrst order processes for the dose range
of interest for relevant human data sets (approximately 0.003–
0.14 mg/kg). Absorption of both Cr(III) and Cr(VI) was estimated
per unit length of the small intestines using the following
equation:
Absorption rate ðmg Cr=hÞ ¼ LKABS ð3Þ
where, L = small intestines length (cm); and KABS = ﬁrst order rate
constant for absorption (mg/cm-h)
Once absorbed, systemic Cr(III) was modeled as belonging to
two general pools: (1) a distributional pool, which describes the
distribution of Cr(III) from the GI tract to tissue via plasma; and
(2) a storage/excretion pool, which describes the release of Cr(III)
from tissues and its ultimate excretion in the urine. For all forms
of chromium, distribution between plasma and systemic tissues
(liver, bone, other) was determined by ‘‘transfer efﬁciency’’ terms,
which are multiplied by tissue blood ﬂows:
Tissue uptake ðmg=hÞ ¼ SFinTECBPQT ð4Þ
where, SFin = Scaling factor applied to transfer efﬁciencies esti-
mated for the mouse [16]; TE = transfer efﬁciency (unitless);
CBP = concentration of chromium in blood plasma (mg/L); and
QT = tissue blood ﬂow rate (L/h).
Similarly, release of Cr from systemic tissues was calculated as
follows:
Tissue release ðmg=hÞ ¼ SFoutTECTQT ð5Þ
where, SFout = Scaling factor applied to transfer efﬁciencies esti-
mated for the mouse [16]; TE = transfer efﬁciency (unitless);
CT = concentration of chromium in systemic tissue (mg/L); and
QT = tissue blood ﬂow rate (L/h).
Data from available human data sets (Table 1) do not provide
speciﬁc information on the distribution of chromium to systemic
tissues. For this reason, transfer efﬁciency terms for systemic tis-
sues were scaled from mouse parameter values (rather than rat
parameter values) since available human data (see Section 4.1)
18 C.R. Kirman et al. / Chemico-Biological Interactions 204 (2013) 13–27indicate that the liver:kidney Cr ratio in humans is greater than
unity (i.e., similar to observations made for the mouse, but not
for the rat). The structure of the human PBPK model for chromium
is depicted in Fig. 3, and the acslX code for the model is provided in
Appendix A.
4.2.2. Model parameterization
4.2.2.1. Physiological parameters. Physiological parameters (body
weight, tissue volumes, tissue blood ﬂows) were obtained from
the published literature [45,55] (Appendix A, Tables A1 and A2).(A) (B
(C)
(E)
(D
Fig. 4. Model predictions for trivalent chromium exposures. Plasma (A) and cumulati
chloride) for three days [30] (required slower clearance from plasma; kintcr = 0.0025, kin
to 0.2 mg Cr(III)/day (as chromium chloride) for up to three months [27–29]. Cumulativ
Cr(III) (as chromium chloride) [34]. Diamonds = data points; error bars = standard deviaGI transit rates, which apply to the transit of chromium and chro-
mium reducing equivalents, were obtained from the published lit-
erature [44]. GI lumen pH and rates for food consumption, saliva
production, and gastric ﬂuid production were obtained from the
published literature [44,47,56,57].
4.2.2.2. GI lumen Cr(VI) reduction. Model parameters for the reduc-
tion of Cr(VI) in the GI tract lumen, including pH-dependent rate
constants and concentrations of reducing equivalents in stomach
contents, are based on ex vivo data and modeling for the data de-)
)
ve urinary excretion (B) for humans exposed to 0.4 mg Cr(III)/day (as chromium
ccr = 0.0004). Plasma (C) and cumulative urinary excretion (D) for humans exposed
e urinary excretion (E) of chromium for humans exposed to a single dose of 0.3 mg
tion; solid line = model predictions.
C.R. Kirman et al. / Chemico-Biological Interactions 204 (2013) 13–27 19scribed in Section 4.1. In humans, gastric pH exhibits diurnal vari-
ation with the consumption of meals, ranging from about 1–5 in
normal adults [24,47,65,67,68]. Unfortunately, information regard-
ing the relative timing of this diurnal variation with respect to
chromium exposures is generally not provided from available hu-
man Cr(III and VI) dosing studies. For this reason, a constant, inter-
mediate value for gastric pH of 2.5 was adopted for ﬁtting the
model to data from human studies. Based upon pH values of 2.5
and 6.5 for lumina of the stomach and small intestines, Cr(VI)
reduction rate constants of 3.7 and 0.067 L/mg-h, respectively,
were calculated using Eq. (1). Model parameters for the reduction
of Cr(VI) in GI tissues were deﬁned as follows. The rate (V/K) of
reduction in GI cells was assumed to be the same as estimated in
rat erythrocytes (71 h1; see below). The value of km for reduction
in GI tissue was assumed to be equal to that estimated in rats and
mice [16]. Model parameters for the reduction of Cr(VI) in systemic
tissues are derived from limited available datasets. Reduction rates
in plasma (0.66 h1) and erythrocytes (71 h1) are based on ﬁts to
in vitro rat data from Richelmi and Baldi [58], and were adopted for
humans as well. Because pH is generally not expected to vary
appreciably within systemic tissues, and because the availability
of intracellular reducing equivalents are not expected to be rate
limiting for low-dose exposures, the reduction value of 71 h1
was applied to all tissues, independent of pH and concentration.
All other model parameters were obtained by adjusting their
values to obtain model predictions that ﬁt available human data
sets based upon visual and statistical optimization. Prior to model-
ing, tissue time-course concentrations for the key data sets (Ta-(A) (B
(C) (D
Fig. 5. Model predictions for chromium in plasma (A) and cumulative urinary excretion
Chromium in plasma (A) and cumulative urinary excretion (B) for humans exposed to a s
(n = 5); error bars = standard deviation; solid lines = model predictions.ble 1) were converted to added chromium, which was calculated
as: (tissue chromium concentration in exposed individuals)-(tissue
chromium concentration in non-exposed individuals). In most
cases, study-speciﬁc information for background levels were used
to calculate added chromium values; however, in cases where
background levels were not clearly provided, information from
other studies were used as indicated in Table 1. Because the study
design of Finley et al. [26] involved repeated exposures to escalat-
ing doses of Cr(VI), with each dose level separated by a period
without exposure, estimates of added chromium were calculated
by subtracting out chromium levels measured prior to each new
exposure period, and each exposure period/dose level was mod-
eled separately. Studies that relied upon exposures to stable iso-
topes of chromium [30,34] did not require subtracting out
background levels to determine added chromium.
4.2.2.3. Cr absorption. The rate constant for absorption of Cr(III) in
the small intestines (kabs3) was adjusted to match the total mass
of chromium excreted in urine (i.e., the last time point for cumula-
tive urinary excretion data). Values for kabs3 were adjusted sepa-
rately for each data set, yielding a range of values (1.3E-06–1.0E-
05 L/h-cm; mean = 4.6E-06 L/h-cm) (Figs. 4–6). The range for kabs3
for data sets involving exposures to chromium chloride (1.3E-06–
1.0E-05 L/h-cm) was similar to that estimated for data sets involv-
ing exposures to chromium picolinate (2.3E-06–9.4E-06 L/h-cm).
The absorption of Cr(III) was greater when administered as Cr(VI)
reduced in orange juice to Cr(III) compared to administration as
chromium chloride [31], requiring an approximate 3-fold increase)
)
(B) for humans exposed to a single dose of 5 mg Cr(III) (as chromium chloride) [31].
ingle dose of 5 mg Cr(III) (as Cr(VI) reduced in orange juice) [31]. diamonds = mean
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achieve agreement with the data, but still falls within the general
range deﬁned by available data sets. The mechanism for this in-
crease is not known, but is similar to the effect of orange juice
on iron absorption, which has been attributed to ascorbic acid
[59,60]. Difﬁculties were encountered in ﬁtting the data from Luka-
ski et al. [33]. Speciﬁcally, adequate ﬁts could be obtained to either
the urine data or plasma data, but not to both simultaneously,
resulting in two estimates for Cr(III) absorption that differ by an or-
der of magnitude (Fig. 6a,b). Greater conﬁdence is put in the(A) (B
(C)
(E)
(D
Fig. 6. Model predictions for chromium picolinate exposures. Plasma (A) and cumulat
picolinate) for 12 Weeks [33]. Simultaneous ﬁts to both plasma and urine data were not
lines; kabs3 = 3.6E-06 L/h-cm) and urinary excretion data (dashed lines; kabs3 = 3.7E-0
humans exposed to 0.4 mg Cr(III)/day (as chromium picolinate) for 12Weeks [32]. Cumu
picolinate) for three days [35]. Diamonds and squares = data; error bars = standard deviabsorption rate estimate based on plasma data since the resulting
value (kabs3 = 3.2E-06 L/cm-h) falls within the range deﬁned by
other data sets, while that based on the urinary excretion data
(kabs3 = 3.3E-05) falls well outside of this range. An explanation
for this difference is not readily apparent.
Exposures to Cr(VI) result in absorption of chromium as both
Cr(III) and Cr(VI). In simulating Cr(VI) data sets, model parameters
for GI lumen reduction, Cr(III) absorption, and Cr(III) clearance
were held constant (e.g., kabs3 was set equal to the mean value
of 4.6E-06 L/h-cm). Model parameter values for Cr(VI) were then)
)
ive urinary excretion (B) for humans exposed to 0.2 mg Cr(III)/day (as chromium
possible, therefore absorption adjusted to provide model ﬁts to plasma data (solid
5). Chromium in plasma, erythrocytes (C), and cumulative urinary excretion (D) in
lative urinary excretion (E) in humans exposed to 0.4 mg Cr(III)/day (as chromium
ation; solid and dashed lines = model predictions.
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plasma, erythrocytes, and urine. The rate constant for absorption of
Cr(VI) in small intestines (kabs6) was adjusted to match the total
mass of Cr excreted in the urine (i.e., last time point in cumulative
urinary excretion plots). Values for kabs6 were set separately for
the Paustenbach et al. [36] and Kerger et al. [31] data sets, ranging
from 2.4-4.0E-04 L/h-cm (mean = 3.2 L/h-cm) (Figs. 7a,b,c,d). Mean
values for the absorption of Cr(III) and Cr(VI) were used to ﬁt the
data of Goulle et al. [42] (Fig. 7e,f), and the oral dose of Cr(VI) (esti-
mated by the authors, but highly uncertain due to vomiting) was
adjusted to provide ﬁts to the urinary excretion data.(A) (B
(C) (D
(F(E)
Fig. 7. Model predictions for hexavalent chromium exposures. Plasma (A) and cumulat
dichromate) for 17 days [36] (required a faster plasma clearance, kincc = 0.06). Plasma (C
Cr(VI)/day (as dichromate) [31]. Plasma, erythrocytes (E), and cumulative urinary exc
Diamonds = data; error bars = standard deviation; solid lines = model predictions.Data are not available regarding the tissue concentrations in hu-
man small intestines following exposures to chromium. For this
reason, tissue concentration data from pigs exposed to Cr(III) in
the diet for 40 days were used as a surrogate [77]. Pigs are consid-
ered to be an appropriate surrogate for the human GI tract, partic-
ularly for the absorption of metals [78]. In this study, tissue levels
of chromium measured in small intestines tissues corresponded to
approximately 2% of total body burden. In modeling the Cr(III) data
sets in humans, the model parameter for the release of Cr(III) from
the small intestines to plasma (kout3) was adjusted to achieve a
relative body burden of 2% for human small intestines. The model
parameter for the release of Cr(VI) from small intestines to plasma)
)
)
ive urinary excretion (B) a single human volunteer exposed to 4 mg Cr(VI)/day (as
) and cumulative urinary excretion (D) in humans exposed to a single dose of 5 mg
retion (F) in an individual exposed to a single dose of Cr(VI) (as chromate) [42].
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tionality with rodent constants [kout6human = kout3human -
⁄ (kout6rodent/kout3rodent), where the average ratio for rodent
parameters was 4.6 [16]].(A)
(B)4.2.2.4. Plasma clearance. Datasets that provide time-course data
(i.e., more than a single data point) for chromium in plasma follow-
ing Cr(III) exposure [30,31] were used to estimate model parame-
ters for systemic clearance of Cr from plasma. Similarly, data sets
that provide time-course data for chromium in plasma following
Cr(VI) exposure [31,36,42], also provide useful information on
the systemic clearance of Cr(III) from plasma, since systemic levels
largely reﬂect Cr(VI) that has been reduced to Cr(III) in the GI tract
and portal system. Early time points for plasma were ﬁt by adjust-
ing model parameter values for systemic tissue uptake from the Cr
distribution pool (SFin, kintrck), while late time points were ﬁt by
adjusting model parameter values for systemic tissue release
(SFout) and renal clearance from the Cr excretion pool (kinccr).
For the data set of Mohamedshah et al. [30], renal clearance for
chromium from blood was best described using slightly lower val-
ues (kintcrk = 0.0025; kinccr = 0.0004) than required for other data
sets. Because the subjects of this study were lactating women, the
change in parameter values may reﬂect changes in chromium
clearance due to lactation. On the other hand, model ﬁts to the data
from the individual studied by Paustenbach et al. [36] required a
slightly faster clearance of Cr during the depuration phase (kin-
ccr = 0.004), than needed for the other data sets.
The rate constant for the uptake of Cr(III) from plasma into
erythrocytes (krbcin3) was set by adjusting ﬁts to the data set of
Volpe et al. [32] (Fig. 6c). The value for the uptake of Cr(VI) into
erythrocytes (krbcin6) and was set by adjusting model ﬁts to the
data of Goullé et al. [42] (Fig. 6e).4.2.2.5. Urinary excretion. Similarly, early time points for urine
were ﬁt by adjusting model parameters for renal clearance from
the Cr distribution pool (kintcrk), while late time points were ﬁt
by adjusting model parameter values for renal clearance from the
Cr excretion pool (kinccr). Parameter values for urinary excretion
rate (kurcc) were adjusted to ﬁt both early and late time points
for urine, while ensuring that liver:kidney tissue predictions by
the model remain above one during exposure period (consistent
with the tissue concentration pattern identiﬁed in Section 3.1).(C)
Fig. 8. Model predictions for chromium in plasma in humans exposed to a single
dose of 10 mg (A), 5 mg (B), or 0.1–1 mg (C) of Cr(VI) (as chromate) [26].
Diamonds = data; error bars = standard deviation; solid lines = model predictions;
dashed line = upper bound estimate of background Cr levels (calculated as pre-
exposure SD⁄1.96).4.2.2.6. High-dose poisoning studies. Attempts to ﬁt the model to
systemic tissue data from high-dose poisoning cases
[37,38,40,41] were unsuccessful. For these data sets the model sub-
stantially overestimated plasma levels while substantially under-
estimating tissue levels of chromium (data not shown). The most
likely explanation for this result is that the Cr(VI) doses in fatal
case studies are well above the dose range evaluated for rodents
(up to approximately 30 mg Cr(VI)/kg [16]). For example the doses
estimated by Kolacinski et al. [39] and Loubieres et al. [40] were
approximately 100 and 350 mg Cr(VI)/kg, respectively. At these
high dose levels, Cr(VI) appears to overwhelm the reduction capac-
ities of the GI lumen, GI tissue, as well as systemic tissues, resulting
in systemic circulation of substantial levels of Cr(VI) that are not
observed with lower-dose exposures. At such high doses, the pat-
tern of tissue concentrations is conceptually consistent with a sys-
tem-wide intracellular ‘‘trapping’’ of Cr in systemic tissues, similar
to the smaller-scale ‘‘trapping’’ of Cr in portal erythrocytes at non-
lethal doses (as discussed in Section 3.1). Because the model has
not been parameterized for systemic distribution of Cr(VI), the
model is not recommended for making predictions of internal dose
when exposures exceed approximately 30 mg Cr(VI)/kg-day.4.2.2.7. Model validation and performance. For the purposes of mod-
el validation, model predictions were compared to the data set
held back from model parameterization (i.e., Finley et al. [26]).
Overall, the model predictions for plasma were in agreement with
plasma data collected at 2 doses levels (5 and 10 mg Cr; Fig. 8).
Unfortunately, the lower dose levels (0.1, 0.5, and 1.0 mg Cr) exam-
ined by Finley et al. [26] yielded plasma levels that were indistin-
guishable from pre-exposure levels, resulting in values for added
Cr that are approximately zero. Model simulations using these
low doses yielded plasma predictions that would be generally
indistinguishable from pre-exposure level variation
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from Finley et al. [26].
The PBPK model provides a reasonable description of the
Cr(III) and Cr(VI) data sets for humans (Figs. 4–8). Model predic-
tions were found to be within a factor of 3 for approximately
84% of the measured data points across all Cr(III) data sets. Over-
all, the model predicts that fraction of ingested Cr(III) absorbed
in these studies is low, ranging from approximately 0.002–0.02
(mean = 0.008). Model predictions were found to be within a fac-
tor of 3 or better for approximately 88% of the measured data
points across Cr(VI) data sets. The predicted fraction of chro-
mium absorbed [as a mixture of Cr(III) and Cr(VI)] is low
(approximately 0.01–0.02) in the studies in which exposure
was spread across multiple doses throughout the day [26,36],
but is considerably higher (0.11) in one study in which exposure
to Cr(VI) occurred as a single bolus dose [31]. The data of Goulle
et al. [42] were best ﬁt by the model using an estimated amount
ingested of approximately 60 mg Cr(VI). This amount is larger
than examined in controlled experiments discussed above, but
is considerably smaller than estimated by the authors (approxi-
mately 3000 mg), suggesting that the majority of Cr(VI) initially
ingested by this individual was lost to vomiting. The PBPK model
predicts that the fraction of Cr absorbed in this study was
approximately 0.3, indicating that the fraction absorbed Cr in-
creases as a function of Cr(VI) dose, which is attributable to
depletion of GI reducing equivalents in the model. For some dataTable 2
Sensitivity analysis.
Dose measure Units P
Cr(VI) ﬂux from stomach lumen (normalized to per kg SI
tissue)
mg/kg-
day
S
S
L
V
V
L
R
1
Cr(VI) ﬂux into SI tissue mg/kg-
day
S
S
S
L
L
V
V
Fraction absorbed Unitless S
L
S
V
S
S
L
Liver:kidney tissue concentration ratio Unitless H
U
S
S
C
S
T
Erythrocyte:plasma concentration ratio Unitless S
S
S
L
L
T
K
* Sensitivity measured by reporting the absolute value for percent change in th
(For example, in the ﬁrst line a 5% change in phs results in a 12.4% change in
internal dose. Simulations for the sensitivity analysis were for 0.05 mg Cr(VI)/ksets, model predictions appear to be shifted slightly to the left
when compared to measured observations (Figs. 5, 7c,d, 8),
which may be due in part to imprecision (i.e., time expressed
on a per day basis, rather than hourly) in the relative timing
of chromium exposure and data collection (e.g., the time until
the ﬁrst data point may be less than the 24 h used to model data
points expressed as day 1).4.2.2.8. Sensitivity analysis. A sensitivity analysis was conducted to
identify model parameters important to predicting internal dose
measures of interest (e.g., for relating to the potential to develop
SI tumors) (Table 2). For measures of Cr(VI) ﬂux (either amount
leaving the stomach lumen normalized to SI tissue weight, or
amount taken up by SI tissue normalized to SI tissue weight), both
of which may be useful for evaluating point of contact effects in the
small intestines, the most sensitive model parameters are GI lumen
pH, GI lumen transit rates, GI lumen reducing equivalent concen-
tration (and rate of regeneration), GI lumen rate of reduction,
and GI lumen and tissue volumes (Table 2). GI lumen pH, SI length,
and SI absorption rate for Cr(III), were the most sensitive model
parameters affecting the fraction of absorbed chromium. For
liver:kidney tissue concentration ratio, hematocrit, urinary excre-
tion rate, SI lumen pH, systemic tissue uptake and release, and car-
diac output were the most sensitive parameters. For
erythrocyte:plasma tissue concentration ratio, GI lumen pH, GI lu-arameter (symbol: sensitivity*)
tomach lumen pH (phs: 12.4%)
tomach lumen transit (klsd: 10.3%)
umen reducing equivalents (cre0: 5.2%)
olume small intestines tissue (vsic: 4.8%)
olume stomach lumen (vslc: 4.7%)
umen reduction rate (kredgifc: 4.5%)
egeneration of gastric reducing equivalents (rfoodc, rgifc, rdrinkc, rsalc:
.3%)
mall intestines lumen pH (phsi: 30.3%)
tomach lumen pH (phs: 12.4%)
tomach lumen transit (klsd: 10.4%)
umen reducing equivalents (cre0: 9.1%)
umen reduction rate (kredgifc: 8.3%)
olume stomach lumen (vslc: 4.8%)
olume small intestines tissue (vsic: 4.8%)
mall intestines lumen pH (phsi: 8.7%)
ength small intestines (lsi: 5.0%)
mall intestines absorption rate (kabs3: 3.6%)
olume small intestines lumen (vsilc: 3.6%)
tomach lumen pH (phs: 3.6%)
tomach lumen transit (klsd: 3.0%)
umen reducing equivalents (cre0: 2.6%)
ematocrit (hct: 6.4%)
rinary excretion (kurcc: 5.0%)
mall intestines lumen pH (phsi: 5.0%)
caling factor, systemic tissue to plasma (SFout: 4.9%)
ardiac output (qcc: 4.6%)
caling factor, plasma to systemic tissue (SFin: 3.5%)
ransfer plasma to kidney (kintcrk: 3.3%)
mall intestines lumen pH (phsi: 15.4%)
tomach lumen pH (phs: 6.7%)
tomach lumen transit (klsd: 5.6%)
umen reducing equivalents (cre0: 5.0%)
umen reduction rate (kredgifc: 4.7%)
ransfer erythrocyte to plasma (krbcout3: 4.3%)
idney blood ﬂow (qkc: 3.9%)
e dose measure value when the model parameter value is increased by 5%.
predicted Cr(VI) ﬂux). The top seven parameters are presented for each
g-day, assuming the dose is spread over ﬁve exposure events per day.
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cyte transfer terms were identiﬁed as the most sensitive.5. Discussion/Conclusions
Several of the datasets used to ﬁt PBPK model parameters in-
cluded data for multiple individuals. The approach of O’Flaherty
et al. [14] was to ﬁt their PBPK model parameters to the data for
each individual separately, principally by varying the rate of Cr(VI)
and Cr(III) absorption across individuals. The authors had noted
another approach would have been to alter their (simplistic) rate
of reduction for achieving ﬁts to total Cr following Cr(VI) dosing.
The approach we used was to average the data across individuals
within a study as a function of added Cr and to use one set of model
parameters to ﬁt the entire study. Fitting data for individuals will
provide greater insight on individual variability; however, the
source of the variability (differences in absorption rate constant,
timing of Cr dose in relation to meals and thus concentration of
reducing equivalents, pH of GI contents, rate of stomach emptying,
etc.) will be unknown. Therefore, the approach we have used for
ﬁtting the model to the average of the study participants provides
estimates of average model parameter values. Assessing sources
and ranges of variation in model parameters will be relevant for
a risk assessment using this model.
The human PBPK model for chromium shares nearly the same
structure as that developed for rats and mice [16]. However, there
are some notable physiological differences between rodents and
humans potentially important for Cr kinetics. First, the rodent fore-
stomach has no human tissue counterpart [61,62]. Because fore-
stomach and glandular stomach were treated as a lumped
compartment in the rodent PBPK model, there was no need to alter
the model structure for humans. Second, there are species differ-
ences in the absorptive surface area of the small intestines
[63,64], which may be an important factor for point of contact ef-
fects. Third, although data from high-dose rodent studies required
inclusion of a saturable absorption algorithm for both Cr(III) and
Cr(VI) [16], this was not required to ﬁt the human data sets since
the Cr(III) data sets were collected at low doses (i.e., below any po-
tential saturation), and the Cr(VI) data sets were either collected at
low-dose repeated exposures or for high-dose acute exposures (i.e.,
too short and/or too low to produce treatment-related effects on
enterocyte turnover that might impact absorption).
An additional important difference between rodents and hu-
mans pertains to variation in key factors that determine the rate
and extent of Cr(VI) reduction. Factors such as gastric lumen pH,
gastric lumen transit time, gastric lumen volumes, and gastric ﬂuid
production, are much more variable in humans than in rodents. As
herbivores with a forestomach to store food and under ad libitum
feeding conditions, mice and rats have relatively consistent stom-
ach conditions with low variability in stomach pH, gastric empty-
ing time, and relatively constant gastric acid production [17,46,57].
In humans, gastric reduction of Cr(VI) is dependent on the presence
of food and pH [24]. Reduction capacity increases in fed conditions
because upon anticipation of eating and distention of the stomach,
signiﬁcant gastric acid, protein and enzyme production occurs [24].
Although food itself contributes additional reducing agents, some
increase in Cr(VI) reductive capacity is likely related to acid and en-
zyme secretion (e.g., reductases that may regenerate reducing
equivalents) that occurs with ingestion of a meal. Basal gastric acid
production between meals in humans is relatively low, 2–5 mEq/
h, but reaches peak rates of 18–23 mEq/h upon food consumption
[47]. Gastric pH is more highly variable in humans than in rodents,
in fasting conditions normal gastric pH ranges from approximately
1–3 in humans, and in fed conditions pH increases to approxi-
mately 4–5 [47,56,57]. Gastric lumen pH has been shown to varywith age [65–68], and also varies between individuals including
potentially sensitive subpopulations (e.g., PPI users). In addition
to being highly variable in humans, many of these parameters (lu-
men pH, gastric emptying time, lumen reducing equivalents) were
identiﬁed in the sensitivity analysis as having a large effect on
model predictions for the ﬂux of Cr(VI) leaving the stomach and ta-
ken up by SI tissue (Table 2). For this reason, characterization of
these important sources of human variation will serve as an impor-
tant component of a PBPK-based human health risk assessment for
chromium.
There are a number of sources of uncertainty in this model,
many of which have been discussed previously for the rodent PBPK
model [16]. Several sources of uncertainties were identiﬁed in the
modeling of Cr(VI) reduction by human gastric contents and are
discussed below.
1. The rate of Cr(VI) reduction in human gastric contents esti-
mated is based upon samples from fasted individuals. Although
changes in gastric reduction capacity due to the presence of
food were addressed using the data of De Flora et al. [24], data
are not available to estimate a different rate of reduction for
individuals in a fed state, and therefore all human modeling
has been performed using fasted state reduction rates.
2. Reducing agents in the GI lumen were modeled as a single
lumped pool of reducing equivalents. Potential reducing agents
in the GI lumen include ascorbic acid, glutathione, other thiol-
containing agents, iron, and potentially numerous other compo-
nents (enzymes, organic material, bacteria, etc.). The participa-
tion of each agent in Cr(VI) reduction may differ during fed vs.
fasted states, and may exhibit different pH-dependence, and
therefore is undoubtedly a more complex process than has been
modeled here. Modeling the reduction of Cr(VI) in gastric ﬂuid
with multiple pools would preferably be based on knowing or
identifying (1) the rate and capacity of reduction for each
source of the reducing agent; (2) how each agent differs (or is
even present) in relation to fasted or fed state, the type of foods
consumed; and (3) the pH dependence of reduction for each
source of reducing agent. However, such information would
be difﬁcult to obtain and a simpler assumption adopted here
of a single reducing pool yielded predictions that are consistent
with the ex vivo data collected as part of this study.
3. A simple, empirical relationship was used to describe the pH
dependence of Cr(VI) based upon available data (Fig. 2c). This
modeling approach used here is similar to that used by other
authors to characterize the pH-dependent reduction of Cr(VI)
by a mixture of organic compounds [74]. The data on which
our pH dependence was characterized includes pooled, fasted
samples collected from normal individuals with a pH between
1 and 4 and a single pooled sample collected from a PPI users
at pH 7 (i.e., no data are available for pH between 4 and 7).
However, the pH dependence may be more complex than mod-
eled here. pH determines the equilibrium of chromate and
dichromate anions present in solution [25], which in turn have
different redox potentials. Accordingly, the pKa for chromate
(5.9) might serve as an inﬂection point for a nonlinear pH
dependence of Cr(VI) reduction.
4. Modeling of the reduction of Cr(VI) in the small intestines
lumen was accomplished by extending the pH-dependent,
mixed second-order model as measured in gastric contents,
with no regeneration of reducing agents in the small intestines.
However, there may be additional processes in the small intes-
tines lumen that contribute to Cr(VI) reduction. For example,
Buerge [72] reported that ferrous iron is capable of reducing
Cr(VI) at high pH. Because the lumen-side membrane of entero-
cytes possess ferrireductase activity, which is required for iron
absorption [73], reduction of Cr(VI) by ferrous iron may reﬂect
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small intestines that has not been addressed in the model. Per-
turbations in iron status in rodents by Cr(VI) exposure [8,16]
may be due in part to the oxidation of ferrous iron by Cr(VI)
in the intestinal lumen.
Additional data for Cr(VI) reduction in: (1) fed human gastric
samples; (2) human gastric samples with pH between 4 and 7;
and (3) the small intestines lumen of rodents and humans, are
identiﬁed as data needs that would help inform key assumptions
made in the PBPK model.
As noted for the rodent model, no data are available for describ-
ing intracellular reduction of Cr(VI) in the small intestines in either
rodents or humans, requiring the use of surrogate data to charac-
terize this reaction (i.e., reduction of Cr(VI) in rat erythrocytes).
In addition, a key source of uncertainty in the human PBPK model
is associated with the fact that the data available for chromium in
exposed humans are primarily limited to plasma, erythrocytes, and
urine. For this reason, consideration was given to combining all
systemic tissues into a single compartment. However, separate
systemic model compartments were maintained for the sake of
consistency with the rodent PBPK model structure [16] and the
previously published model [14]. In addition, separate model com-
partments permit a comparison between model predictions for
liver:kidney data, for which limited data are available in humans
following low-level exposures to Cr(III) [43,44] and fatal poison-
ings with Cr(VI) [37,38,40].
Another source of uncertainty pertains to the relative timing of
Cr(VI) exposure events compared to the state of the GI tract (i.e.,
fed or fasted states) and the timing of sample (urine and blood) col-
lection. For the sake of simplicity in ﬁtting available human data
sets, for which information regarding relative timing of exposure
and GI state are lacking, constant daily average values were
adopted for model parameters that are known to vary between
fed and fasted states (lumen pH, gastric emptying, Cr(VI) reduction
capacity). Averaging data across individuals in a study, who are
presumably reﬂect a mixture of persons exposed in fed or fasted
states, helps to mitigate the potential impact of effect this uncer-
tainty. Furthermore, the timing in relation to Cr dose and sample
collection impacts the ﬁts to early time points in the human PK
datasets. Having additional information on timing of doses and
sample collection might improve model ﬁts to early time points.
Overall, the PBPK model developed here provides a good
description of Cr(III) and Cr(VI) toxicokinetics in humans based
upon available data, with model predictions falling within a factor
of 3 or better for approximately 86% [84% for Cr(III), 88% for Cr(VI)]
of the available data points from a wide range of study protocols,
dose levels and Cr species. Furthermore, the PBPK model predic-
tions are consistent with the key patterns (liver:kidney and eryth-
rocyte:plasma ratios discussed in Section 3.1) identiﬁed for
chromium. Model predictions for liver:kidney ratios were approx-
imately 2.9 for the exposure scenarios evaluated, which falls in the
middle of the range of 1.4–4.3 identiﬁed from the published liter-
ature [37,38,40,43,44]. Similarly predictions for the erythro-
cyte:plasma ratio are less than one for Cr(III) exposures, which is
consistent with the observed data of Volpe et al. [32]; while pre-
dicted ratios greater than one are consistent with observed data
for high-dose exposures to Cr(VI) [39,40,42].
PBPK modeling in human health risk assessment for chromium
will permit evaluation of the uncertainty and variability in both the
rodent and human model predictions for the dose measure(s) se-
lected. By accounting for key species differences, sources of satura-
ble toxicokinetics, and sources of uncertainty and variation, the
rodent PBPK model [16] and human PBPK model presented here
should provide risk managers with a more robust characterization
of interspecies variability and improved extrapolation of rodentbioassay results to environmentally-relevant exposures in human
populations.
6. Notes
The DUHS IRB has determined that protocol ID: Pro00028884,
for the collection of human stomach ﬂuids, meets the deﬁnition
of research not involving human subjects as described in 45 CFR
46.102(f), 21 CFR 56.102(e) and 21 CFR 812.3(p) and satisﬁes the
Privacy Rule as described in 45 CFR 164.514.
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